Femi Soremekun, managing director of Nigeria-based Biofem Pharmaceuticals, is all too familiar with the fight against counterfeit drugs. In late 2008, a distributor notified him that he suspected that one of Biofem’s products, Glucophage, was being counterfeited. After checking batch and inventory numbers, Soremekun reassured him there was no evidence of such activity. It was only after more allegations surfaced that he sent a sample to French manufacturer Merck & Co. to be analyzed. Turns out the claims were correct. “I was very shocked,” Soremekun says. “[The counterfeiters] got into my market, counterfeited my product, and I wasn’t even aware of it. I was losing sales.”
